← Back
Elanco Animal Health
ELAN · listed on the New York Stock Exchange · worth $12.04 billion
$24.10
+4.51% on Nov 2
Eleven insider buys in the last year, $2.61 million in all. None in the last two weeks.
Green dot = an insider bought red = sold◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
495.4M shares
99% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, seven insiders bought Elanco Animal Health stock and one insider sold. Every one of the 1 sale is marked on its filing as planned in advance; all by company executives.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
Director
Lawrence Erik Kurzius
Bought $935.9K on Aug 20 — 40,000 shares at $23.40, 21% of what they now own.
2 of 2 earlier purchases did better than the S&P 500
PRESIDENT, CEO AND DIRECTOR
Jeffrey N. Simmons
Bought $478.5K on Dec 11, 2025 — 22,000 shares at $21.75, held through a trust or family, 13% of what they now own.
1 of 1 earlier purchase did better than the S&P 500
Director
Paul Herendeen
Bought $236.8K on Aug 7 — 10,000 shares at $23.69, 9.0% of what they now own.
No earlier purchases to measure
Planned sales
Form 144 notices filed for Elanco Animal Health in recent months, beside the Form 4 sales reported after each. A notice says a person intends to sell; it is not a sale.
Timothy J. Bettington filed to sell 4,350 shares on 15 Oct; sold 4,350 by 15 Oct10b5-1 plan adopted 15 Jun 2026 · Notice on SEC.gov
All reports
Every insider trade and SEC report we hold for Elanco Animal Health.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Oct 19SoldTimothy J. BettingtonOct 19 · Traded Oct 15 · SEE REMARKS · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.4,350 @ $23.00$100K
7 more with Pro →Analysts, earnings and news
Analysts' price target
$31.21 average
14 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
4 of 4 quarters above
Q2 '26$0.34 a share+$0.07
Q1 '26$0.40 a share+$0.06
Q4 '25$0.13 a share+$0.01
Q3 '25$0.19 a share+$0.06